PMID- 20081802
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 23
IP  - 4
DP  - 2010 Apr
TI  - 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with 
      histological types and prognosis.
PG  - 619-28
LID - 10.1038/modpathol.2009.185 [doi]
AB  - In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is 
      thought to be a marker of good prognosis in oligodendroglial tumors. However, 1p 
      and 19q loss of heterozygosity may be telomeric, interstitial, centromeric or 
      affect the whole arm of the chromosome and the associations between these 
      different patterns and tumor type, other molecular markers and patient prognosis 
      remain unclear. We analyzed microsatellite markers in a region spanning the 
      chromosome from the telomere to the centromere, to characterize the pattern of 1p 
      and 19q loss of heterozygosity in 39 infiltrative gliomas, including 
      astrocytomas, glioblastomas, oligoastrocytomas and oligodendrogliomas. We then 
      studied the association between loss of heterozygosity and the expression of p53 
      protein and Olig2, as analyzed using immunohistochemistry, and epidermal growth 
      factor receptor (EGFR) gene amplification, as investigated using fluorescence in 
      situ hybridization (FISH). Finally, we assessed the influence of molecular 
      markers on the overall survival of patients. We identified five different 1p19q 
      loss of heterozygosity patterns among the tumors studied and found that loss of 
      heterozygosity over the whole 1p arm was associated with loss of heterozygosity 
      over the whole 19q arm in 90% of cases. 1p19q whole loss was present in all the 
      classical oligodendrogliomas, whereas other 1p19q loss patterns predominated in 
      oligoastrocytomas. 1p19q whole loss was also significantly associated with Olig2 
      overexpression, but was never observed in tumors overexpressing p53 protein. We 
      also found that, among patients with contrast-enhancing tumors, those with 1p19q 
      whole loss tended to survive for longer. In combination with classical 
      histological and immunohistochemical data, 1p19q status determination provides 
      pertinent information useful for (1) discriminating between histological types of 
      gliomas and (2) identifying a subgroup of tumors that are associated with a 
      better prognosis.
FAU - Durand, Karine S
AU  - Durand KS
AD  - Department of Pathology, Dupuytren University Hospital, Limoges, France.
FAU - Guillaudeau, Angelique
AU  - Guillaudeau A
FAU - Weinbreck, Nicolas
AU  - Weinbreck N
FAU - DeArmas, Rafael
AU  - DeArmas R
FAU - Robert, Sandrine
AU  - Robert S
FAU - Chaunavel, Alain
AU  - Chaunavel A
FAU - Pommepuy, Isabelle
AU  - Pommepuy I
FAU - Bourthoumieu, Sylvie
AU  - Bourthoumieu S
FAU - Caire, Francois
AU  - Caire F
FAU - Sturtz, Franck G
AU  - Sturtz FG
FAU - Labrousse, Francois J
AU  - Labrousse FJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100115
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (OLIG2 protein, human)
RN  - 0 (Oligodendrocyte Transcription Factor 2)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Basic Helix-Loop-Helix Transcription Factors/*genetics
MH  - Biomarkers, Tumor/*genetics
MH  - Brain Neoplasms/*genetics/mortality/pathology
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Chromosomes, Human, Pair 19/genetics
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Gene Amplification
MH  - Glioma/*genetics/mortality/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Loss of Heterozygosity
MH  - Male
MH  - Microsatellite Repeats
MH  - Middle Aged
MH  - Nerve Tissue Proteins/*genetics
MH  - Oligodendrocyte Transcription Factor 2
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Tumor Suppressor Protein p53/*genetics
EDAT- 2010/01/19 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - S0893-3952(22)02742-9 [pii]
AID - 10.1038/modpathol.2009.185 [doi]
PST - ppublish
SO  - Mod Pathol. 2010 Apr;23(4):619-28. doi: 10.1038/modpathol.2009.185. Epub 2010 Jan 
      15.